Economic and cost-effectiveness in evaluating the value of cardiovascular therapies. The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy.
Califf
R M
RM
Duke Clinical Research Institute, Durham, NC 27715, USA.
Stump
D
D
Topol
E J
EJ
Mark
D B
DB
D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D003657:Decision Making; D005343:Fibrinolytic Agents / Q000191:economics* / Q000627:therapeutic use; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy; D009656:North America; D012189:Retrospective Studies; D013300:Streptokinase / Q000191:economics* / Q000627:therapeutic use; D015912:Thrombolytic Therapy / Q000191:economics*; D010959:Tissue Plasminogen Activator / Q000191:economics* / Q000627:therapeutic use
D005343:Fibrinolytic Agents; D013300:Streptokinase; D010959:Tissue Plasminogen Activator